Enanta Pharmaceuticals Investor Relations Material
Latest events
Q1 2024
Enanta Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Enanta Pharmaceuticals Inc
Access all reports
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. It focuses on developing its late-stage product candidates that target non-structural protein 3 protease (NS3/4A) of hepatitis C virus (HCV) and compounds targeting NS5A of HCV. The company's lead clinical candidate, paritaprevir, is developed in collaboration with AbbVie in a combination therapy regimen for the treatment of genotype 1 HCV; EDP-522 as an NS5A inhibitor for the treatment of chronic hepatitis B virus; and EDP-239 as an HCV NS3 protease inhibitor.
Key slides for Enanta Pharmaceuticals Inc
Q1 2024
Enanta Pharmaceuticals Inc
Q1 2024
Enanta Pharmaceuticals Inc
Latest articles
Sundar Pichai: CEO of Alphabet and Google
Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.
19 Apr 2024
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States